<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817271</url>
  </required_header>
  <id_info>
    <org_study_id>D1020C00018</org_study_id>
    <nct_id>NCT00817271</nct_id>
  </id_info>
  <brief_title>To Evaluate the Response to Glucagon During Hypoglycemia</brief_title>
  <official_title>A Randomised, Open, Two-Way Cross-Over, Phase I Study to Evaluate the Response to Glucagon Versus the Spontaneous Counter-Regulatory Response in T2DM Patients Treated With AZD1656 and Metformin During Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the response to Glucagon versus the spontaneous
      hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and
      Metformin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P-Glucose levels</measure>
    <time_frame>Repeated sampling during the 24 hour period on day 5 and 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)</measure>
    <time_frame>Frequent measurements during the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables (Area under the plasma conc-time curve from time 0 to 24 hours post dose (AUC0-24), maximum plasma conc(Cmax), time to reach maximum plasma conc(tmax), terminal elimination half-life and apparent oral clearance</measure>
    <time_frame>Repeated sampling during the 24 hour period on day 5 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (P-Glucose, S-Insulin and S-C-peptide)</measure>
    <time_frame>Repeated sampling during the 24 hour period on day 5 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1656</intervention_name>
    <description>Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type II diabetes patients, female with non child-bearing potential

          -  T2DM diagnosis confirmed by C-peptide &gt;0.3nmol/L and no glutamic acid decarboxylate
             (GAD) antibodies at enrolment (screening)

          -  Treatment with metformin alone with a total daily dose not less than 1 000 mg. Stable
             glycaemic control indicated by unchanged treatment within 3 months prior to enrolment

        Exclusion Criteria:

          -  History of ischemic heart disease, symptomatic heart failure, stroke, transitory
             ischemic attack or symptomatic peripheral vascular disease

          -  Signs of diabetic proliferative retinopathy or diabetic maculopathy, at screening or
             on an ophthalmological examination within 3 months from start of study

          -  Participating in another clinical study during the last 30 days prior to enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klas Malmberg, MD, PhD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D MÃ¶lndal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcus Hompesch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut for Clinical Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>May 6, 2009</last_update_submitted>
  <last_update_submitted_qc>May 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Klas Malmberg, MD, PhD, Prof. Medical Science Director, Emerging Products</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Type II Diabetes</keyword>
  <keyword>Counter-regulatory response</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

